News

The chief of Oncology and Hematology at University of Nebraska Medical Center, discussed the potential utility of CAR T-cell therapy across the non-Hodgkin lymphoma (NHL) paradigm.

The 4-day virtual conference will feature plenary presentations, workshops, and bootcamps led by cell therapy industry leaders with expertise in discovery, development, manufacturing, and more.

Both Vertex and Arbor are adding to their list of gene and cell therapy partnerships with the announcement.

The chief executive and chief medical officers of Celyad Oncology discussed their platform and positive data presented at EHA 2021.

The 2 companies will focus their strategic partnership on the development of gene therapies for rare diseases, as well.

Mariya Moosajee, MBBS, BSc, PhD, FRCOphth, discussed the next generation of gene therapy for inherited retinal diseases.

The CAR T therapy tisagenlecleucel missed its EFS endpoint in the phase 3 BELINDA trial for B-cell non-Hodgkin lymphoma.

The research director at the Moran Eye Center discussed the genetics of developing age-related macular degeneration.

Presentations at ISTH 2021 revealed attributes most important to patients when considering gene therapies and where further research is needed.

Stephen M. Ansell, MD, PhD, discussed the potential of using non–CAR T-based novel approaches in the non-Hodgkin lymphoma treatment paradigm.

Salvador Rico, MD, PhD, chief medical officer, Encoded Therapeutics, discussed the different initiatives the company is conducting in Dravet syndrome.

FT516 and FT595 are both currently being evaluated in phase 1 trials for B-cell malignancies.

KITE-363 is set to be investigated in a phase 1 clinical trial at the end of 2021.

The 2-dose vaccine has been approved for use 9 months after its Emergency Use Authorization (EUA).

Edward Holland, MD, chief medical advisor, discussed an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.

CAR T-cell therapy use will likely expand to a wider array of hematologic malignancies.

Nina Shah, MD, and other experts discuss the role of CAR T-cell therapy in relapsed/refractory multiple myeloma.

Iuliana Vaxman, MD, and Angela Dispenzieri, MD, review eligibility criteria for ASCT in AL amyloidosis, conditioning dosing, efficacy in terms of hematologic and organ response, and future areas of research.

The FDA previously approved ide-cel as the first BCMA-directed CAR T-cell therapy for patients with relapsed/refractory multiple myeloma following 4 or more prior lines of therapy.

Kelly Garvin, BSN, RN, OCN, discussed methods to communicate the benefits and risks of CAR T-cell therapy to patients and recognize AEs.

The chief scientific officer and chief medical officer of Ultragenyx Gene Therapy discussed the company’s future research in gene therapies.

Mustang Bio plans to file an IND and start a phase 1 clinical trial as soon as a lead construct is identified.

Investigators sought to understand the mechanisms of transferred T cell proliferation and expression.

Jennifer Buell, PhD, president and chief operating officer of Agenus, discussed the VISION platform the company uses to develop therapies.

Krina K. Patel, MD, MSc, discussed moving away from chemotherapy and toward immunotherapy.

With a new paradigm of treating previously incurable diseases comes a new pay paradigm for million-dollar therapies.

Kevin Heller, MD, executive vice president of research, Jasper Therapeutics, discussed future research with JSP191.

Julie Vose, MD, professor of internal medicine and division chief, Division of Oncology and Hematology, University of Nebraska Medical Center, discussed the use of CAR T-cell therapy in non-Hodgkin lymphoma.